大行评级|花旗:微升国药控股目标价至20.5港元,维持“买入”评级

格隆汇
Yesterday
花旗发表报告指,国药控股第三季收入大致符合预期,纯利略优于市场预期,主要受惠于有效费用控制。第三季收入1448亿元,同比大致持平;毛利率同比收窄4个基点至6.8%;销售费用率同比下降11个基点,带动总经营费用率下降10个基点至3.6%;净利率同比扩大5个基点至1.3%,支持应占纯利同比增长4%至19.1亿元。该行维持对其“买入”评级,目标价由20.4港元微升至20.5港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10